This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lohrisch, C. Articles by Olivotto, I. A. Search for Related Content PubMed PubMed Citation Articles by Lohrisch, C. Articles by Olivotto, I. A. Social Bookmarking                            What's this?

Relationship Between Tumor Location and Relapse in 6,781 Women With Early Invasive Breast Cancer

From the Breast Cancer Outcomes Unit and Systemic and Radiation Therapy Programs of the British Columbia Cancer Agency, and Fraser Valley Cancer Centers and the Faculty of Medicine, University of British Columbia, Vancouver, Canada.

Address reprint requests to Caroline Lohrisch, MD, FRCPC, Investigation Drug Branch for Breast Cancer, Bd de Waterloo 125, 1000 Brussels, Belgium; email carolinebrussels{at}hotmail.com

PURPOSE: To explore the independent prognostic impact of medial hemisphere tumor location in early breast cancer.

PATIENTS AND METHODS: A comprehensive database was used to review patients referred to the British Columbia Cancer Agency from 1989 to 1995 with early breast cancer. Patients were grouped according to relapse risk (high or nonhigh) and adjuvant systemic therapy received. Multiple regression analysis was used to determine whether the significance of primary tumor location (medial v lateral hemisphere) was independent of known prognostic factors and treatment.

RESULTS: In the adjuvant systemic therapy groups, medial location was associated with a 50% excess risk of systemic relapse and breast cancer death compared with lateral location. Five-year systemic disease-free survival rates were 66.3% and 74.2% for high-risk medial and lateral lesions, respectively (P < .005). Corresponding 5-year disease-specific survival rates were 75.7% and 80.8%, respectively (P < .03). No significant differences were observed between medial and lateral location for low-risk disease regardless of adjuvant therapy or for high-risk disease with no adjuvant therapy. Local recurrence rates were similar for all risk and therapy groups.

CONCLUSION: The two-fold risk of relapse and breast cancer death associated with high-risk medial breast tumors may be due to occult spread to internal mammary nodes (IMNs). Enhanced local control, such as with irradiation of the IMN chain, may be one way to reduce the excess risk. Ongoing randomized controlled trials may provide prospective answers to the question of the optimal volume of radiotherapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J. Spillane, F. Noushi, R. A. Cooper, V. Gebski, and R. F. Uren High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer Ann. Onc., June 1, 2009; 20(6): 977 - 984. [Abstract] [Full Text] [PDF]

				A. I. So, R. J. Levitt, B. Eigl, L. Fazli, M. Muramaki, S. Leung, M. C.U. Cheang, T. O. Nielsen, M. Gleave, and M. Pollak Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer Clin. Cancer Res., November 1, 2008; 14(21): 6944 - 6954. [Abstract] [Full Text] [PDF]

				R. C. Chen, N. U. Lin, M. Golshan, J. R. Harris, and J. R. Bellon Internal Mammary Nodes in Breast Cancer: Diagnosis and Implications for Patient Management--A Systematic Review J. Clin. Oncol., October 20, 2008; 26(30): 4981 - 4989. [Abstract] [Full Text] [PDF]

				M. S. Yao, B. F. Kurland, A. H. Smith, E. K. Schubert, L. K. Dunnwald, D. R. Byrd, and D. A. Mankoff Internal Mammary Nodal Chain Drainage Is a Prognostic Indicator in Axillary Node-Positive Breast Cancer Ann. Surg. Oncol., October 1, 2007; 14(10): 2985 - 2993. [Abstract] [Full Text] [PDF]

				B Klaeser, O Wiederkehr, D Koeberle, A Mueller, B Bubeck, and B Thuerlimann Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer Ann. Onc., August 1, 2007; 18(8): 1329 - 1334. [Abstract] [Full Text] [PDF]

				S. Sarp, G. Fioretta, H. M. Verkooijen, G. Vlastos, E. Rapiti, H. Schubert, A.-P. Sappino, and C. Bouchardy Tumor Location of the Lower-Inner Quadrant Is Associated with an Impaired Survival for Women With Early-Stage Breast Cancer Ann. Surg. Oncol., March 1, 2007; 14(3): 1031 - 1039. [Abstract] [Full Text] [PDF]

				M. C.U. Cheang, D. O. Treaba, C. H. Speers, I. A. Olivotto, C. D. Bajdik, S. K. Chia, L. C. Goldstein, K. A. Gelmon, D. Huntsman, C. B. Gilks, et al. Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival J. Clin. Oncol., December 20, 2006; 24(36): 5637 - 5644. [Abstract] [Full Text] [PDF]

				A. Tran, B. S. Pio, B. Khatibi, J. Czernin, M. E. Phelps, and D. H.S. Silverman 18F-FDG PET for Staging Breast Cancer in Patients with Inner-Quadrant Versus Outer-Quadrant Tumors: Comparison with Long-Term Clinical Outcome J. Nucl. Med., September 1, 2005; 46(9): 1455 - 1459. [Abstract] [Full Text] [PDF]

				M. Colleoni, D. Zahrieh, R. D. Gelber, S. B. Holmberg, J. E. Mattsson, C.-M. Rudenstam, J. Lindtner, D. Erzen, R. Snyder, J. Collins, et al. Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience J. Clin. Oncol., March 1, 2005; 23(7): 1390 - 1400. [Abstract] [Full Text] [PDF]

				R. L. Wahl, B. A. Siegel, R. E. Coleman, and C. G. Gatsonis Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group J. Clin. Oncol., January 15, 2004; 22(2): 277 - 285. [Abstract] [Full Text] [PDF]

				I. A. Olivotto, B. Chua, S. J. Allan, C. H. Speers, S. Chia, and J. Ragaz Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer J. Clin. Oncol., March 1, 2003; 21(5): 851 - 854. [Abstract] [Full Text] [PDF]

				D. K. Gaffney, A. Tsodikov, and C. L. Wiggins Diminished Survival in Patients With Inner Versus Outer Quadrant Breast Cancers J. Clin. Oncol., February 1, 2003; 21(3): 467 - 472. [Abstract] [Full Text] [PDF]

				R. Arriagada, M. G. Le, G. Contesso, J. M. Guinebretiere, F. Rochard, and M. Spielmann Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer Ann. Onc., September 1, 2002; 13(9): 1404 - 1413. [Abstract] [Full Text] [PDF]

				W. B. Eubank, D. A. Mankoff, J. Takasugi, H. Vesselle, J. F. Eary, T. J. Shanley, J. R. Gralow, A. Charlop, G. K. Ellis, K. L. Lindsley, et al. 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer J. Clin. Oncol., August 1, 2001; 19(15): 3516 - 3523. [Abstract] [Full Text] [PDF]